<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02121340</url>
  </required_header>
  <id_info>
    <org_study_id>R34EY024299</org_study_id>
    <nct_id>NCT02121340</nct_id>
  </id_info>
  <brief_title>Collaborative Care for Depression and Diabetic Retinopathy in African Americans</brief_title>
  <acronym>CC-DDR</acronym>
  <official_title>Collaborative Care for Depression and Diabetic Retinopathy in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this feasibility/pilot study, we will develop, refine, and evaluate the feasibility of a
      novel mental health/ophthalmologic intervention called, &quot;Collaborative Care for Depression
      and Diabetic Retinopathy&quot; (CC-DDR), which aims to treat depression and lower HbA1C in older
      African Americans with mild-to-moderate diabetic retinopathy (DR) and comorbid depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Specific Aims are:

        1. To develop the CC-DDR treatment protocol. This will involve:

             1. Creating an initial version of the CC-DDR treatment protocol.

             2. Refining the protocol based on input from an expert panel with expertise in DR,
                depression, and culturally relevant interventions for diabetes in older African
                Americans.

             3. Developing a tool to assess interventionist treatment adherence and competence.

        2. To conduct an open trial of CC-DDR with 40 participants who have poorly controlled
           diabetes, depression, and mild or moderate DR. During this open trial we will:

             1. Evaluate the feasibility of CC-DDR.

             2. Refine the CC-DDR treatment protocol by incorporating feedback from participants,
                community health care workers (CHWs), ophthalmologists, and the expert panel.

             3. Refine procedures for recruitment and retention, outcome assessment, monitoring
                treatment fidelity, CHW training and supervision, quality assurance, and study
                administration, based on input from investigators, CHWs, participants, and the
                expert panel.

             4. Examine CC-DDR's impact on depression severity; diabetes self-management practices;
                HbA1C level; blood pressure; adherence to the ophthalmologist treatment plan;
                vision function; quality of life; and satisfaction with CC-DDR.

        3. To complete a Manual of Procedures that characterizes all aspects of the planned
           efficacy trial of CC-DDR.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>12 months</time_frame>
    <description>Change in hemoglobin A1c from baseline to 12 months</description>
  </primary_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement in depressive symptoms from baseline to 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression of diabetic retinopathy</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes self management</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement from baseline to 12 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Behavioral Activation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Activation</intervention_name>
    <arm_group_label>Behavioral Activation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. African-American race

          2. age ≥ 65 years

          3. type 2 diabetes

          4. mild or moderate nonproliferative DR with or without macular edema

          5. depressive symptoms (i.e., Patient Health Questionnaire-9 score ≥5)

          6. HbA1C ≥ 7.0%

        Exclusion Criteria:

          1. treated proliferative DR

          2. global cognitive impairment (i.e., Mini Mental Status score ≤ 20)

          3. psychiatric diagnosis other than depression

          4. treatment for depression started in the previous 3 months

          5. life expectancy under 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Rovner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Casten, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Health disparities</keyword>
  <keyword>African American</keyword>
  <keyword>Geriatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

